LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?

Alessandro Russo; Paola Muscolino; Christian Rolfo

doi:10.1016/j.medj.2023.12.002

LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?

Med. 2024 Feb 9;5(2):112-114. doi: 10.1016/j.medj.2023.12.002.

Authors

Alessandro Russo¹, Paola Muscolino², Christian Rolfo³

Affiliations

¹ Department of Onco-Hematology, Papardo Hospital, Messina, Italy.
² Department of Onco-Hematology, Papardo Hospital, Messina, Italy; Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy.
³ Center for Thoracic Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: christian.rolfo@mssm.edu.

PMID: 38340705
DOI: 10.1016/j.medj.2023.12.002

Abstract

The recently published results of LIBRETTO-431¹ pave the way for a new standard of care in the first-line setting for RET-fusion-positive NSCLCs, which raises important clinical questions not only in the therapeutic landscape of advanced NSCLC but also in the drug development process in the era of uncommon molecular subtypes.

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Clinical Trials, Phase III as Topic
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Proto-Oncogene Proteins c-ret / genetics
Proto-Oncogene Proteins c-ret / therapeutic use
Randomized Controlled Trials as Topic

Substances

Proto-Oncogene Proteins c-ret